Announcement from C.Q. pharmaceutical holding: Net income attributable to shareholders of the listed company is expected to be between 220 million yuan and 260 million yuan from January 1, 2024 to June 30, 2024, a decrease of 49.38% to 57.17% year-on-year. Net income after deducting non-recurring gains and losses is expected to be between 200 million yuan and 240 million yuan, a decrease of 49.33% to 57.78% year-on-year. The decline in performance is mainly due to the decrease in gross margin caused by the policy of volume-based procurement and the increase in expected credit impairment losses caused by the extension of the accounts receivable aging period. Specific financial data will be disclosed in detail in the 2024 semi-annual report.
重药控股：预计上半年净利润同比下降49.38%至57.17%
C.Q. pharmaceutical holding: it is expected that the net income for the first half of the year will decrease by 49.38% to 57.17% year-on-year.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.